bioAffinity Technologies, Inc.
BIAF · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 269.7% | 52,617.1% | – | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 36.1% | 31.3% | 90.3% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -89% | -301.3% | -116,777.7% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -96.6% | -313.5% | -169,771.2% | – |
| EPS Diluted | -22.5 | -27.3 | -54.3 | -25.8 |
| % Growth | 17.6% | 49.7% | -110.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |